Product
Droxidopa
Aliases
L-DOPS, L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, Northera
Name
Northera
INN Name
droxidopa
FDA Approved
Yes
6 clinical trials
1 organization
12 indications
1 document
Indication
Primary Autonomic FailureIndication
FibromyalgiaIndication
Dopamine beta-hydroxylase deficiencyIndication
Peripheral NeuropathyIndication
Neurogenic Orthostatic HypotensionIndication
Orthostatic HypotensionIndication
Menkes DiseaseIndication
Occipital Horn SyndromeIndication
Autonomic FailureIndication
Multiple System AtrophyIndication
Parkinson's diseaseClinical trial
A Multi-center, Open-label Study to Assess the Long-term Safety of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic HypotensionStatus: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With FibromyalgiaStatus: Completed, Estimated PCD: 2011-10-01
Clinical trial
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa TherapyStatus: Completed, Estimated PCD: 2022-07-21
Clinical trial
Treatment Trial of Droxidopa and Pyridostigmine to Improve Orthostatic Hypotension Without Aggravating Supine HypertensionStatus: , Estimated PCD: 2025-05-01
Clinical trial
Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical TrialStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2Status: Recruiting, Estimated PCD: 2024-09-01
Document
DailyMed Label: NortheraOrganization
Lundbeck Pharmaceuticals LLC